Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician's choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

被引：0
|
作者：
Ryan, Charles J.
Watkins, Simon Paul
Despain, Darrin
Karlovich, Chris Alan
Simmons, Andrew
Golsorkhi, Anthony A.
Chowdhury, Simon
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Clovis Oncol, Boulder, CO USA
[3] Clovis Oncol, Bethesda, MD USA
[4] Guys Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS5087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5087
引用
收藏
页数：5
相关论文
共 50 条
  • [1] TRIAL OF RUCAPARIB IN PROSTATE INDICATIONS 3 (TRITON3): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, OPEN-LABEL PHASE 3 STUDY OF RUCAPARIB VS PHYSICIAN'S CHOICE OF THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)
    Krieger, Laurence
    Byard, Ian
    Clay, Timothy
    Ganju, Vinod
    Ryan, Charles J.
    Watkins, Simon
    Despain, Darrin
    Simmons, Andy
    Miyamoto, Emiko
    Golsorkhi, Tony
    Chowdhury, Simon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 50 - 50
  • [2] TRITON3: An International, Randomised, Open-Label Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associate with Homologous Recombination Deficiency (HRD)
    Merseburger, A.
    Carl, S.
    Feyerabend, S.
    Gleissner, J.
    Grimm, M. -O.
    Gruellich, C.
    Heidenreich, A.
    Heinrich, B.
    Miller, K.
    Stenzl, A.
    Steuber, T.
    Wirth, M.
    Watkins, S.
    Simmons, A.
    Passler, L.
    Shetty, S.
    Golsorkhi, T.
    Ryan, C.
    Chowdhury, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 74 - 74
  • [3] TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
    Ryan, Charles J.
    Abida, Wassim
    Bryce, Alan Haruo
    Balar, Arjun Vasant
    Dumbadze, Igor
    Given, Robert W.
    Morris, David
    Petrylak, Daniel Peter
    Redfern, Charles H.
    Scher, Howard I.
    Watkins, Simon Paul
    Simmons, Andrew
    Passler, Luke
    Golsorkhi, Tony
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] TRIAL OF RUCAPARIB IN PROSTATE INDICATIONS 2 (TRITON2): AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL PHASE 2 STUDY OF THE PARP INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)
    Shapiro, Jeremy
    Voskoboynik, Mark
    Krieger, Laurence
    Byard, Ian
    Clay, Timothy
    Ganju, Vinod
    Abida, Wassim
    Chowdhury, Simon
    Watkins, Simon
    Despain, Darrin
    Simmons, Andy
    Go, Jowell
    Golsorkhi, Tony
    Scher, Howard I.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 61 - 61
  • [5] TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
    Abida, Wassim
    Bryce, Alan Haruo
    Balar, Arjun Vasant
    Chatta, Gurkamal S.
    Dawson, Nancy Ann
    Guancial, Elizabeth A.
    Hussain, Arif
    Jha, Gautam Gopalji
    Lipsitz, David Uri
    Patnaik, Akash
    Petrylak, Daniel Peter
    Ryan, Charles J.
    Stanton, Thomas S.
    Vogelzang, Nicholas J.
    Zhang, Jingsong
    Simmons, Andrew
    Go, Jowell
    Golsorkhi, Tony
    Chowdhury, Simon
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [6] TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD)
    Heidenreich, A.
    Carl, S.
    Feyerabend, S.
    Gleissner, J.
    Gruellich, C.
    Heinrich, B.
    Merseburger, A.
    Miller, K.
    Stenzl, A.
    Steuber, T.
    Wirth, M.
    Watkins, S.
    Simmons, A.
    Go, J.
    Golsorkhi, T.
    Abida, W.
    Scher, H. I.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 75 - 75
  • [7] The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Chowdhury, S.
    Abida, W.
    Arranz Arija, J.
    Daugaard, G.
    Fizazi, K.
    Gez, E.
    Heidenreich, A.
    Joly Lobbedez, F.
    McDermott, R.
    Merseburger, A. S.
    Piulats Rodriguez, J. M.
    Sautois, B.
    Sridhar, S.
    Sternberg, C. N.
    Watkins, S.
    Simmons, A.
    Shetty, S.
    Golsorkhi, A.
    Ryan, C. J.
    Scher, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Second-Line Therapy for Patients with metastatic castration-refractory Prostate Cancer (mCRPC) An international, randomized, open-label, Phase 3 Study of the PARP Inhibitor Rucaparib versus Physicians Choice of Treatment for Patients with metastatic castration-resistant Prostate Cancer (mCRPC) associated with homologous Recombination Deficiency (TRITON3) - AP 100/18 of the AUO
    Rexer, H.
    Graefen, M.
    Merseburger, A.
    AKTUELLE UROLOGIE, 2019, 50 (05) : 478 - 479
  • [9] The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Cora, N. S.
    Sergio, B.
    Ugo, D. G.
    Giuseppe, P.
    Simon, C.
    Wassim, A.
    Angel, A. A. Jose
    Gedske, D.
    Karim, F.
    Eliahu, G.
    Axel, H.
    Florence, J.
    Ray, M.
    Axel, S. M.
    Maria, P. Josep
    Brieuc, S.
    Srikala, S.
    Tony, G.
    Charles, J. R.
    Howard, I. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] The Triton Clinical Trial Programme: Evaluation of the Parp Inhibitor Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated With Homologous Recombination Deficiency (HRD)
    Krieger, Laurence
    Shapiro, Jeremy
    Byard, Ian
    Campbell, David
    Clay, Timothy
    Ganju, Vinod
    Watkins, Simon
    Simmons, Andy
    Go, Jowell
    Shetty, Sanjay
    Golsorkhi, Tony
    Abida, Wassim
    Ryan, Charles J.
    Scher, Howard I.
    Chowdhury, Simon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 164 - 164
12345